Increased risk of pancreatic, thyroid, prostate and breast cancers in men with a family history of breast cancer: A population-based study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Song, Huiyeon | - |
dc.contributor.author | Jung, Yoon Suk | - |
dc.contributor.author | Tran, Thi Xuan Mai | - |
dc.contributor.author | Moon, Chang Mo | - |
dc.contributor.author | Park, Boyoung | - |
dc.date.accessioned | 2023-10-10T02:50:53Z | - |
dc.date.available | 2023-10-10T02:50:53Z | - |
dc.date.created | 2023-06-19 | - |
dc.date.issued | 2023-09 | - |
dc.identifier.issn | 0020-7136 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/191928 | - |
dc.description.abstract | The association between a family history of breast cancer (FHBC) in female first-degree relatives (FDRs) and cancer risk in men has not been evaluated. This study aimed to compare the risks of overall and site-specific cancers in men with and without FHBC. A population-based study was conducted with 3 329 106 men aged ≥40 years who underwent national cancer screening between 2013 and 2014. Men with and without FHBC in their female FDRs were age-matched in a 1:4 ratio. Men without FHBC were defined as those without a family history of any cancer type in their FDRs. Data from 69 124 men with FHBC and 276 496 men without FHBC were analyzed. The mean follow-up period was 4.7 ± 0.9 years. Men with an FHBC in any FDR (mother or sister) had a higher risk of pancreatic, thyroid, prostate and breast cancers than those without an FHBC (adjusted hazard ratios [aHRs] (95% confidence interval [CI]): 1.35 (1.07-1.70), 1.33 (1.12-1.56), 1.28 (1.13-1.44) and 3.03 (1.130-8.17), respectively). Although an FHBC in any one of the FDRs was not associated with overall cancer risk, FHBC in both mother and sibling was a significant risk factor for overall cancer (aHR: 1.69, 95% CI:1.11-2.57) and increased the risk of thyroid cancer by 3.41-fold (95% CI: 1.10-10.61). FHBC in the mother or sister was a significant risk factor for pancreatic, thyroid, prostate and breast cancers in men; therefore, men with FHBC may require more careful BRCA1/2 mutation-related cancer surveillance. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | John Wiley and Sons Inc | - |
dc.title | Increased risk of pancreatic, thyroid, prostate and breast cancers in men with a family history of breast cancer: A population-based study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Boyoung | - |
dc.identifier.doi | 10.1002/ijc.34573 | - |
dc.identifier.scopusid | 2-s2.0-85161278570 | - |
dc.identifier.wosid | 000999382900001 | - |
dc.identifier.bibliographicCitation | International Journal of Cancer, v.153, no.5, pp.950 - 957 | - |
dc.relation.isPartOf | International Journal of Cancer | - |
dc.citation.title | International Journal of Cancer | - |
dc.citation.volume | 153 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 950 | - |
dc.citation.endPage | 957 | - |
dc.type.rims | ART | - |
dc.type.docType | Article; Early Access | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | BRCA1 | - |
dc.subject.keywordPlus | MUTATIONS | - |
dc.subject.keywordAuthor | breast cancer family history | - |
dc.subject.keywordAuthor | cancer risk | - |
dc.subject.keywordAuthor | cancers | - |
dc.subject.keywordAuthor | men | - |
dc.identifier.url | https://onlinelibrary.wiley.com/doi/10.1002/ijc.34573 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.